Bcl-2 Gene Expression

Last Modified: October 18, 2006

Share article


Dear OncoLink "Ask The Experts,"

My wife, age 22, was diagnosed with stage IIIA clear cell adenocarcinoma of the cervix. Is it true that if Bcl-2 staining is found in the tumor, then that would make it more resistant to conventional treatments? Are there any approved therapies for such resistant tumors (i.e. targeting Bcl-2)?


Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:

Bcl-2 gene expression is common in many tumor types and has been associated with chemotherapy resistance. At the University of Pennsylvania, we will soon be conducting a clinical trial that attempts to reverse the resistance caused by Bcl-2 gene expression, but no US FDA-approved therapies currently exist.

Standard treatment of locally advanced cervical cancer consists of radiation and radiation-sensitizing chemotherapy. The standard therapy for recurrent or persistent disease is platinum-based combination chemotherapy. In the setting where standard therapies have failed, clinical trials of newer agents may be available in your area.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More